180 related articles for article (PubMed ID: 9166518)
21. Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells.
Budillon A; Tagliaferri P; Caraglia M; Torrisi MR; Normanno N; Iacobelli S; Palmieri G; Stoppelli MP; Frati L; Bianco AR
Cancer Res; 1991 Feb; 51(4):1294-9. PubMed ID: 1997168
[TBL] [Abstract][Full Text] [Related]
22. IL-1 and TNF transmodulate epidermal growth factor receptors by a protein kinase C-independent mechanism.
Bird TA; Saklatvala J
J Immunol; 1989 Jan; 142(1):126-33. PubMed ID: 2783320
[TBL] [Abstract][Full Text] [Related]
23. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.
Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM
J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.
Shaw JP; Akiyoshi DE; Arrigo DA; Rhoad AE; Sullivan B; Thomas J; Genbauffe FS; Bacha P; Nichols JC
J Biol Chem; 1991 Nov; 266(31):21118-24. PubMed ID: 1939154
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture.
Imai Y; Leung CK; Friesen HG; Shiu RP
Cancer Res; 1982 Nov; 42(11):4394-8. PubMed ID: 6290036
[TBL] [Abstract][Full Text] [Related]
26. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
27. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE
Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182
[TBL] [Abstract][Full Text] [Related]
28. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
30. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
31. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
32. Growth-inhibitory effects of epidermal growth factor on human breast cancer and carcinoma of the esophagus transplanted into nude mice.
Murayama Y
Ann Surg; 1990 Mar; 211(3):263-8. PubMed ID: 2155590
[TBL] [Abstract][Full Text] [Related]
33. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
34. Ligand depletion negatively controls the mitogenic activity of epidermal growth factor.
van de Poll ML; van Rotterdam W; Gadellaa MM; Jacobs-Oomen S; van Zoelen EJ
Exp Cell Res; 2005 Apr; 304(2):630-41. PubMed ID: 15748906
[TBL] [Abstract][Full Text] [Related]
35. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown.
Huang WC; Hsu RM; Chi LM; Leu YL; Chang YS; Yu JS
Cancer Lett; 2007 Apr; 248(1):137-46. PubMed ID: 16919867
[TBL] [Abstract][Full Text] [Related]
36. Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells.
Lössner D; Abou-Ajram C; Benge A; Reuning U
Int J Biochem Cell Biol; 2008; 40(12):2746-61. PubMed ID: 18577466
[TBL] [Abstract][Full Text] [Related]
37. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
38. Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration.
Murphy LJ; Murphy LC; Vrhovsek E; Sutherland RL; Lazarus L
Cancer Res; 1984 May; 44(5):1963-8. PubMed ID: 6324992
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
40. Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid.
Kosano H; Takatani O
Cancer Res; 1988 Nov; 48(21):6033-6. PubMed ID: 3262419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
